Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. (Q53254173)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Serena Amici

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

10

Blennow K

1 reference

2 November 2019

8

Vanmechelen E

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

3

Sjögren M

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

9

Parnetti L

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Fodero LR

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Andreasen N

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Gallai V

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Vanderstichele H

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Small DH

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 May 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuroscience Research

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

520-526

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

2 November 2019

cites work

1 reference

Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development--a study of molecular forms

21 January 2018

1 reference

Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: selective loss of the intermediate (10S) form

21 January 2018

1 reference

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease

21 January 2018

1 reference

Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type.

21 January 2018

1 reference

Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition.

21 January 2018

1 reference

21 January 2018

1 reference

Cholinesterases and the Pathology of Alzheimer Disease

21 January 2018

1 reference

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

21 January 2018

1 reference

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

21 January 2018

1 reference

APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques.

21 January 2018

1 reference

Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.

21 January 2018

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease.

21 January 2018

1 reference

Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia.

21 January 2018

1 reference

Is mild cognitive impairment prodromal for vascular dementia like Alzheimer's disease?

21 January 2018

1 reference

Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains.

21 January 2018

1 reference

Mild cognitive impairment represents early-stage Alzheimer disease

21 January 2018

1 reference

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

21 January 2018

1 reference

Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.

21 January 2018

1 reference

Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain.

21 January 2018

1 reference

Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

21 January 2018

1 reference

Altered glycosylation of cerebrospinal fluid butyrylcholinesterase in Alzheimer's disease.

21 January 2018

1 reference

Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer's disease.

21 January 2018

1 reference

Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

21 January 2018

1 reference

Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.

21 January 2018

1 reference

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

21 January 2018

1 reference

Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease

21 January 2018

1 reference

Functional deficits in patients with mild cognitive impairment: prediction of AD.

21 January 2018

1 reference

Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease.

21 January 2018

1 reference

The Mini-Mental State Examination: A Comprehensive Review

21 January 2018

1 reference

Neuropathology of preclinical and clinical late-onset Alzheimer's disease.

21 January 2018

1 reference

Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer's type, other types of dementia, and control subjects.

21 January 2018

1 reference

Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex

21 January 2018

1 reference

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

21 January 2018

1 reference

Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders

21 January 2018

1 reference

Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.

21 January 2018

1 reference

Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment.

21 January 2018

1 reference

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

21 January 2018

1 reference

Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system

21 January 2018

1 reference

Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups

21 January 2018

1 reference

The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JNR.10599

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12704813%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference